Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board

SAN DIEGO - September 26, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), announced today that Dr. Stephen Z. Fadem has agreed to join the company's Extracorporeal Science Advisory Board. Dr. Fadem is active as a practicing Houston nephrologist, teacher, lecturer and researcher. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine, Baylor College of Medicine.

Dr. Fadem is also a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology and diplomate of the American Board of Quality Assurance and Utilization Review Physicians. He has served as the Chairman of the (National Kidney Foundation (NKF) of Southeast Texas Medical Advisory Board, and has received their Lifetime Achievement Award and the Myron L. Jenkins Award.
On a national level, Dr. Fadem is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients (AAKP), and a past vice-president of the AAKP Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD Networks, was a member of the CMS Clinical Performance Measures Committee. He serves as a consultant to the computer industry in the development of CKD management software and is the founder of Touchcalc, a software design company. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, and computer technology and computer security. Dr. Fadem is the co-editor of AAKP Renalife, and is a reviewer for several peer-reviewed journals.
Dr. Fadem has been nationally recognized, receiving the AAKP Nova Award, the NKF Distinguished Service Award. He has also received the NKF Presidents Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He has also been named as one of America's Top Doctors by Castle Connolly and US News and World Report.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Gains 40% on News

New York, NY - September 25, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID) trading up over 40% following news today.
The Company reported an update to its stockholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/ today/ investorideas.com
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) To Present at the Exosomes and Microvesicles 2012 Conference

SAN DIEGO - September 25, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), disclosed today that its Chairman and CEO, Jim Joyce will present at the Exosomes and Microvesicles 2012 conference, which is being hosted by The American Society for Exosomes and Microvesicles. The event will be held at the Wyndham Lake Buena Vista Resort in Orlando, Florida and runs from September 29th through October 2nd. Mr. Joyce's presentation is scheduled for 10:10 a.m. on October 2nd and is entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy. Additional information on the event can be found online at www.exosomesandmicrovesicles.org.

The Aethlon Medical presentation will review the attributes of the Aethlon Hemopurifier® as an adjunct medical device that can be combined with chemo and immunotherapies as a strategy to improve cancer treatment outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biotech Stock News: Sunshine Biopharma's (OTCBB: SBFM) Adva-27a Preclinical Research Results to Be Published in October Issue of ANTICANCER RESEARCH

MONTREAL - September 25, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that its paper on Adva-27a preclinical research results has been accepted and will be published in the October issue of ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment.

Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal (Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology (http://ar.iiarjournals.org).
Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Cientifica (SIIC) Databases.
About Sunshine Biopharma Inc. (OTCBB : SBFM ):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer (www.sunshinebiopharma.com).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contact:
For Additional Information
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biodefense Stock Breaking News: PositiveID Corporation (OTCBB: PSID) Comments on Department of Homeland Security's Revised Procurement Strategy for BioWatch Generation 3, Phase II

DELRAY BEACH, Fla. - September 24, 2012 - (Investorideas.com Newswire) PositiveID Corporation (OTCBB: PSID) ("PositiveID" or "Company"), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing, today provided an update to its stockholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").

The purpose of BioWatch Generation 3, Phase II is to obtain a fully autonomous networked biodetection capability that will be deployed, operated, and sustained, both indoor and outdoor, in selected U.S. BioWatch jurisdictions to continuously monitor the air for agents of biological concern. The original procurement outlined in the draft solicitation released by DHS in August 2011, with an estimated contract value of $3.1 billion, contemplated a single procurement resulting in a single award Indefinite Delivery Indefinite Quantity (IDIQ) contract for Performance Testing, Low Rate Initial Production (LRIP), Operational Test & Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The revised strategy, released by DHS two weeks ago, would consist of a two-stage procurement using a competitive down-selection between stages. Stage 1 would be for Performance Testing of candidate systems and may result in the award of multiple contracts depending on the technical merits of proposals submitted and the availability of funding. Stage 2 would be a separate competition and result in the award of a single contract for LRIP, OT&E, Full Rate Production, Deployment, Sustainment and Disposal. To be considered for the Stage 2 award, a company would need to demonstrate a design maturity and data set equivalent to that of Stage 1 participants.
William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe the revised strategy for BioWatch, allowing for performance testing of qualifying systems in preparation for the full roll-out of the $3.1 billion procurement, provides us an opportunity to prove our M-BAND system, the only system of its kind that was demonstrated previously in the field under the DHS S&T BAND Program. Additionally, we continue to have discussions with potential strategic partners to prepare the Company for success in BioWatch Gen-3, Phase II."
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that it has made significant progress realigning its business with a focus on its molecular diagnostics platform; the likelihood that the Company also continues to make strong progress in the diabetes management segment of its business; the likelihood that the Company will enter into strategic partnerships and/or teaming agreements with large government contractors for M-BAND manufacturing and system integration for BioWatch Gen-3; the likelihood that the Company will submit a proposal upon release of the final BioWatch Gen 3 RFP, currently scheduled for release in the fourth quarter of calendar 2012, from Department of Homeland Security for the $3.1 billion BioWatch Gen-3 procurement; the likelihood that the Company will commence the second stage of Easy Check clinical study at Schneider Children's Medical Center in Israel; the likelihood that the Company will complete a bench-top unit of the GlucoChip glucose-sensor and initiate strategic partnerships; the likelihood that the Company will continue development of its Dragonfly Rapid MDx Cartridge-based diagnostic system for point-of-care diagnostics; the likelihood that the Company will complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the likelihood that the Company will complete a strategic financing to capitalize the Company to execute on these opportunities; the likelihood that significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of the Company's innovative Dragonfly system; the likelihood that the Company will continue to execute its plan, described above; the likelihood that the Company is well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products; the likelihood that that progress, in conjunction with a strategic financing to fully capitalize the Company, will allow the Company to unlock value for stockholders; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its M-BAND system and Dragonfly system, as well as its diabetes management products; the Company's ability to complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the Company's ability to attract strategic partners; the Company's ability to complete a strategic financing; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on August 20, 2012, May 14, 2012, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Healthcare Stock Breaking News: GreeneStone (OTCBB:GRST) Addresses Eating Disorder Epidemic with Expanded Clinical Staff and Clinic Launch in Autumn 2012

September 21, 2012 (Investorideas.com newswire) GreeneStone Healthcare Corporation (OTCBB:GRST), provider of Mental Healthcare and Corporate Healthcare Services, today announced the hiring of Ann Kerr as Clinical Director at its new Eating Disorder clinic. In addition to Ms. Kerr, the Company has chosen a psychiatrist medical director, head psychologist, and Chief Clinical Advisor, all of whom will formally be announced once they are under contract. In addition the recently announced new hire, Dr. Mohsina Chaklader, at the company’s ‘ Center of Excellence for Gastroenterology’ will be a valuable resource for the Eating Disorder clinic.

In the United States, as many as 10 million females and 1 million males are suffering from an eating disorder such as anorexia and bulimia and millions more are struggling with binge eating disorders. While awareness of eating disorders is improving, the public, health care providers and educators frequently have little understanding of eating disorders, how to recognize symptoms and how to communicate with people dealing with eating disorders. Eating disorders are very difficult to treat and can require lifelong treatment. The goal of the Company will be to stay with and support patients throughout their time of need, while striving to achieve sufficient improvement so that in-patient care is reduced and outpatient and ongoing care can begin.
Corporate Healthcare and disability costs are growing steadily higher and effective treatment for those suffering from mental health and mental health related issues will be the solution to reducing those costs. The Company has an increasing number of specialists in the treatment of mental health related disorders. “These are by far the largest component of corporate healthcare costs,” stated Mr. Shawn Leon, CEO. He added, “We see this as the biggest area of growth for the Company and we need to be national in scope.”
Ann Kerr is a Registered Occupational Therapist and holds academic appointments as Assistant Professor in the Department of Psychiatry, and Lecturer in the Department of Occupational Therapy in the Faculty of Medicine at The University of Toronto. She has worked in the field of mental health for over 30 years and specialized in the care for people affected by eating disorders through work in Inpatient, Day Hospital, community, and private practice settings. Ann was part of the team that built the Inpatient Eating Disorder Program at Toronto General Hospital under Dr. Sid Kennedy, and then the first ever Eating Disorder Day Hospital Program with Drs Allan Kaplan and Niva Piran. Ann accepted the position of the first Program Director of Sheena’s Place, an innovative model of support services for families and people with eating disorders. Ann has been in private practice in Toronto for the past six years honing her psychotherapy skills in the areas of CBT, DBT and Relational Therapy.
Ann was trained at The University of Toronto and has ongoing education through Harvard Medical School of Continuing Education and the Jean Baker Miller Centre at Wellesley College. She has supervised students in most health professions and been awarded the Northrop Frye teaching award for medical student education. Ann was on the Board of the Transitional College of Occupational Therapists and is a Member of the College of Occupational Therapists of Ontario and the Ontario Association of Occupational Therapists. She is a member of the Academy of Eating Disorders, an international body of eating disorder clinicians and researchers. Ann has written research articles and chapters in books on the treatment of people with eating disorders as well as having spoken at numerous conferences in Canada and the USA. She has appeared frequently on television, radio and in newspapers and magazines commenting on current issues in the culture that relate to this issue.
Limited operations at the Eating Disorder clinic are set to begin in late October, with full service operations intended to commence in early 2013. The primary mission of the clinic will be to treat anorexia and bulimia through a combination of services, including in-patient care, intensive outpatient care, ongoing support, after-care and counseling. The company plans to offer the very best in care and hopes to earn a reputation for the best care available in the country.
About GreeneStone Healthcare Corporation
GreeneStone Healthcare Corp. (GRST) is a provider of mental health services, specializing in the areas of addiction treatment, eating disorders, nutrition and weight loss, and executive healthcare. GreeneStone is among the many nascent healthcare companies re-defining the healthcare space for the modern economy, which include Roche Holding Ltd. (RHHBY), Sarepta Therapeutics Inc. (SRPT), Nektar Therapeutics (NKTR), Celldex Therapeutics, Inc. (CLDX), Achillion Pharmaceuticals, Inc. (ACHN), Zogenix, Inc. (ZGNX). The company operates medical and healthcare clinics in Ontario, Canada, serving a North American and international clientele. GreeneStone’s clinics meet several ends: (1) GreeneStone adds overflow capacity to an increasingly stretched public healthcare system in Canada, (2) GreeneStone mental health clinics provide private alternatives to publicly available but highly underserviced healthcare subsectors, and (3) GreeneStone meets newly developing healthcare needs undisturbed by the public/private market, such as eating disorders. The company is headquartered in Toronto, Canada.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as “expect,” “plan,” “will,” “may,” “anticipate,” “believe,” “should,” “intend,” “estimate,” and variations of such words. Forward-looking statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, those risks and uncertainties contained in this press release and those identified in the periodic reports that the company files with the Securities and Exchange Commission (the “SEC”) pursuant to the Exchange Act.
Investor information and email sign-up:
http://www.greenestoneinvestor.com
Contact:.
GreeneStone Healthcare Corporation
Shawn Leon, 416-222-5501
investor@greenestoneinvestor.com
www.greenestoneinvestor.com
Published at the Investorideas.com Newswire
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com was compensated five hundred for the publication and distribution of this news release .
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Shares Move Following News of Advancing to Next Phase of Drug Development with Lead Anti-Cancer Compound, Adva-27a

New York, New York - September 13, 2012 (Investorideas.com Newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues a trading alert and chart for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading at $0.28, up 0.07 or 33.33% as of 1:55PM EDT on over 121,000 shares.

Sunshine Biopharma announced today an update on progress which has enabled the Company to advance to the next phase of drug development, namely GMP manufacturing, IND-enabling studies and Phase I clinical trials in humans.
"We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing, and recent fund raising efforts," said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.
Read the full news: http://www.investorideas.com/CO/ SBFM/news/2012/ 09131.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com